Saturday, September 25, 2021 |
Tweet Review: 'Love Story', first day, first showModi meets global CEOs to sell India invest pitchAriyana Glory Gifts Herself a New CarGHMC remains worst Covid-hit in TelanganaMegastar Launches Rousing Republic TrailerIndia records 26,964 fresh Covid cases, active count lowest in 186 daysPooja Hegde Has No Time for ThemMore rains forecast for Telangana, two weather systems at work'Exams Alone Don't Make Life': Actor SuriyaIndia logs 30,256 new COVID-19 cases, 295 fatalities

Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

Posted September 2nd, 2021, 10:12 AM IST

Biological E gets drug regulator's approval to conduct phase 2/3 trials on children

The Drug Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct Phase 2 & 3 clinical trials for its anti-COVID shots called Corbevax on children between 5 and 18 years of age with certain conditions, sources told ANI.

The trial will be conducted in ten locations.





The permission has been given to Biological E after the recommendation from the Subject Expert Committee.

Meanwhile, Zydus Cadila's needle-free COVID-19 vaccine ZyCoV-D has already received emergency use authorisation (EUA) to inoculate children in the age group of 12-18. It is expected to be administered from the first week of October.

The trials of Bharat Biotech's Covaxin COVID-19 vaccine for phases 2 & 3 for children are underway, and its result is expected in September.

It is to be noted that the government has made an advance payment of Rs 1,500 crore to Biological E for 30 crore vaccines.

Sharing

advertisement
Videos